HMGBiotech is a biotech company that provides reagents, services and ideas to researchers and companies active in the HMGB field.

The only producer of quality-controlled redox variants of HMGB1

Featured news

A study just published on ASCO’s Journal of Clinical Oncology focuses on how lung metastasis remains a significant challenge in treating Triple Negative Breast Cancer (TNBC).

Recent progresses in proteomics have unveiled promising pathways for early cancer detection and treatment.

HMGB1 (High Mobility Group Box 1) isoforms can be used to explore the mechanisms of several disease models.
All proteins are LPS free, so they are suitable for in vitro and in vivo researches.

Fully reduced HMGB1
All the three cysteines are completely reduced. HMGB1 acts as potent chemoattractant for many cells type. Read more…

Disulfide HMGB1 
If two cysteines have a disulfide bond. HMGB1 acts as proinflammatory mediator. Read more…

Terminally oxidized HMGB1
The three cysteines are oxidized to sulfonate. HMGB1 is inactive. Read more…

From our LinkedIn profile

About us

HMGBiotech has R&D and production unit within Ospedale San Raffaele, one of the leading research institutes in Italy as per volume and quality of scientific output. Read more about our company…
Shopping Cart